What is RCKT's market cap?

$286.51M, based on the Nov 4 close of $2.61.

Does Rocket Pharmaceuticals pay a dividend?

No regular cash dividend has been paid in the last year.

How much of RCKT is sold short?

16.3M shares, 19.2% of float, as of Oct 15, 2026.

What sector is RCKT in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · RCKTHealthcarePharmaceuticals

Rocket Pharmaceuticals, Inc. Common Stock (RCKT)

$2.61+3.98%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$2.51▼ 29.49% in range

Nov 3, 2025Low $2.18 · High $5.30Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Rocket Pharmaceuticals closed at $2.61 on Nov 4, up 3.98%, 50.8% below its 52-week closing high. Volume of 1.7M shares was 0.77× its 20-day average (below normal).

Split-adjusted performance: +5.2% over one month, -32.4% over six months, -26.7% over one year.

Short interest was 16.3M shares at the Oct 15 settlement, up 8.2% from the prior report (19.2% of float, 6.7 days to cover).

Market cap$286.5M109.8M shares

Revenue · quarter$0.00—

Diluted EPS$1.08—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range2.18 – 5.30−50.8% from high

Volume1.7M0.77× 20-day avg

Volatility · 60d66.6%Annualised

Short % of float19.2%6.7 days to cover

Net cash$262.5MCash $283.7M

Next earnings—Not scheduled

Split-adjusted performance

1W +1.2%1M +5.2%3M −26.3%6M −32.4%YTD −25.6%1Y −26.7%3Y −85.8%5Y −91.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum42

Revenue growth—

Net margin—

Value (low P/E)—

Size53

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short16.3M+8.2% vs prior

Days to cover6.7Settled Oct 15

% of float19.2%

Short vol. 10d49.1%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
RCKTRocket Pharmaceuticals	$2.61	+3.98%	−32.4%	—	—	—	$286.5M
LRMRLarimar Therapeutics	$2.76	+8.66%	−33.5%	—	—	—	$286.7M	Compare
FULCFulcrum Therapeutics	$3.77	+0.80%	−47.0%	—	—	—	$288.0M	Compare
VOGXVogenx	$19.73	−3.90%	—	—	—	—	$293.1M	Compare
TTRXTurn Therapeutics	$9.80	+3.05%	+158.2%	—	—	—	$297.6M	Compare
BIOABioAge Labs	$5.95	−0.17%	−67.8%	+1.6%	−1064.7%	—	$273.1M	Compare
EBSEmergent Biosolutions	$5.90	−5.60%	−35.2%	−52.4%	−29.7%	—	$302.5M	Compare
SPRYARS Pharmaceuticals	$3.05	0.00%	−67.1%	+114.2%	−185.2%	—	$303.3M	Compare
QTTBQ32 Bio	$8.97	+2.40%	+64.0%	—	—	7.9	$267.0M	Compare

News about Rocket Pharmaceuticals

All news →

No recent articles focused on Rocket Pharmaceuticals.

Quick answers

What does Rocket Pharmaceuticals do?: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases.
What is RCKT's market cap?: $286.51M, based on the Nov 4 close of $2.61.
Does Rocket Pharmaceuticals pay a dividend?: No regular cash dividend has been paid in the last year.
How much of RCKT is sold short?: 16.3M shares, 19.2% of float, as of Oct 15, 2026.
What sector is RCKT in?: Healthcare, in the Pharmaceuticals industry.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

HQ: New York, NY202 employeesListed Feb 18, 2015rocketpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology